Imaging and Selective Drug Delivery to Lung Tumor Using Molecular Signature-Targeted Peptide Probes
의약학 > 내과학
이병헌 , ( In San Kim ) , ( Jae Yong Park )
대한결핵 및 호흡기학회
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 145(총1페이지)
0y909798.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    A growing number of evidence shows that pathological lesions put their own molecular signatures on their tissues and blood vessels. Peptide probes that recognize such molecular signatures can be used in targeted delivery of imaging agents and therapeutics to the diseased tissue. Peptides have smaller size and in turn may exert better tissue penetration than bulky antibodies. Using phage displayed-random peptide libraries, for example, we have identified an IL-4 receptor-binding peptide-1 (IL4rPep-1, CRKRLDRNC). IL-4 receptor (IL4R) is known to be over-expressed on many types of human cancer cells including lung cancer. IL4rPep-1 selectively bound to H226 lung tumor cells that over-express IL4R, while little binding was observed in H460 lung tumor cells that express IL4R at low levels. In vivo fluorescence imaging detected higher levels of homing of IL4R-targeted, fluorescent liposomes to a subcutaneous H226 tumor of mice than that of untargeted liposomes. In addition, IL4R-targeted liposomes containing doxorubicin showed more efficient anti-tumor growth activity than untargeted liposomes. These results suggest that the molecular signature-targeted peptide-mediated imaging and drug delivery is a useful tool for cancer detection and therapy.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.